Citations

Abstract Background/aims The rate of recurrent small-bowel bleeding (SBB) remains high despite the advent of balloon assisted enteroscopy (BAE). The study aims were to determine: (1) the diagnostic and therapeutic yields, and adverse event rate of repeat BAE in SBB, and (2) the predictors of a positive repeat BAE. Methods A retrospective review of a BAE database was conducted. Patients who had > 1 BAE for SBB were included. Primary outcomes were diagnostic yield, therapeutic yield, and adverse events of repeat BAE. Secondary outcomes were predictors of a positive repeat BAE. Results A total of 175 patients (55 % men; mean age 64.1 ± 16.3 years) were included. The diagnostic and therapeutic yields of repeat BAE were 55 % and 42 %, respectively. Repeat BAE adverse events occurred in 5 % with self-limited abdominal pain being most common. Patients with a positive repeat BAE were significantly older than the negative group (68.6 ± 13.9 vs. 60.9 ± 17.1; P = 0.001) and were more likely to have cardiac comorbidities (OR 2.4, 95 %CI: 1.3 – 4.6; P = 0.01), chronic kidney disease (OR 2.3, 95 %CI: 1.1 – 4.9; P = 0.04), chronic obstructive pulmonary disease (OR 3.3, 95 %CI: 1.3 – 8.1; P = 0.01), positive initial BAE (OR 3.6, 95 %CI: 1.9 – 6.8; P < 0.001), and antegrade procedure (OR 3.3, 95 %CI: 1.7 – 6.1; P < 0.001). On multivariate analysis, a positive initial BAE and antegrade route were the only significant predictive factors. Conclusions Performing a repeat BAE for SBB appears safe and provided modest yields. A positive initial BAE and antegrade route were predictive of a positive repeat BAE.

Ultrafast plane wave imaging enables acquisition and accumulation of a large number of Doppler ensembles in a short period of time, which substantially boosts ultrasound Doppler sensitivity by at least an order of magnitude. As a key component, spatiotemporal clutter filtering based on singular value decomposition (SVD) has recently demonstrated superior performance in tissue clutter suppression and microvessel signal extraction over conventional high-pass-filter-based clutter filtering techniques. This presentation introduces several novel SVD clutter filter techniques from our recent work, focusing on addressing the technical challenges (complex tissue motion, high computational cost, and noise) of SVD clutter filter during clinical translations of the ultrafast microvessel imaging technology for human imaging. We present a block-wise adaptive SVD filter method that can robustly threshold singular values on a local level, a real-time feasible SVD clutter filtering method based on partial SVD and randomized spatial downsampling, and a noise equalization and suppression method that can significantly improve microvessel imaging quality at a low cost. In vivo performance of these methods will be demonstrated in different organs.

Key Points We conducted the first exome-wide association study between germ line variant genotype and survival outcomes after unrelated-donor BMT. A number of novel genes were found to significantly affect survival outcomes.

AbstractBecause of the rapidly growing use of ultrasound shear wave elastography (SWE) in clinical practices, there is a significant need for development of clinical physics performance assessment methods for this technology. This study aims to report two clinical medical physicists’ tasks: (a) acceptance testing (AT) of SWE function on ten commercial ultrasound systems for clinical liver application and (b) comparison of SWE measurements of targets across vendors for clinical musculoskeletal application. For AT, ten GE LOGIQ E9 XDclear 2.0 scanners with ten C1‐6‐D and ten 9L‐D transducers were studied using two commercial homogenous phantoms. Five measurements were acquired at two depths for each scanner/transducer pair by two operators. Additional tests were performed to access effects of different coupling media, phantom locations and operators. System deviations were less than 5% of group mean or three times standard deviation; therefore, all systems passed AT. A test protocol was provided based on results that no statistically significant difference was observed between using ultrasound gel and salt water for coupling, among different phantom locations, and that interoperator and intraoperator coefficient of variation was less than 3%. For SWE target measurements, two systems were compared — a Supersonic Aixplorer scanner with a SL10‐2 and a SL15‐4 transducer, and an abovementioned GE scanner with 9L‐D transducer. Two stepped cylinders with diameters of 4.05–10.40 mm were measured both longitudinally and transaxially. Target shear wave speed quantification was performed using an in‐house MATLAB program. Using the target shear wave speed deduced from phantom specs as a reference, SL15‐4 performed the best at the measured depth. However, it was challenging to reliably measure a 4.05 mm target for either system. The reported test methods and results could provide important information when dealing with SWE‐related tasks in the clinical environment.

Abstract BACKGROUND Clinical trials NRG/NSABP B-31 and Alliance/NCCTG N9831 demonstrated that trastuzumab added to chemotherapy extended disease-free survival (DFS) in breast cancer patients (pts) in the adjuvant setting (Romond et al). However, the degree of trastuzumab benefit varies among pts. We previously described an 8-gene model that was predictive for trastuzumab benefit, which was validated in an independent cohort of B-31 patients (Pogue-Geile 2013). The 8-gene signature subtyped B-31 pts in an independent validation cohort into three trastuzumab benefit groups: one with large benefit HR=0.27, one with medium benefit HR=0.56, and one with little to no benefit HR=1.56. The purpose of this study was to validate the 8-gene model in pts enrolled into N9831, which tested the efficacy of adding trastuzumab to doxorubicin plus cyclophosphamide → paclitaxel by randomizing pts into one of three arms: chemotherapy only (Arm A), trastuzumab given after chemotherapy (Arm B), or trastuzumab given concurrently with chemotherapy (Arm C). METHODS NCounter data, consisting of 8 predictive genes and 4 house-keeping genes, for 1,379 patients enrolled into N9831 were used to assign each patient to one of the three benefit groups. Assignments to one of the three trastuzumab benefit groups based on the 8-gene model were made by the NSABP/NRG Pathology Laboratory Biostatistician, who was blinded to outcome data. Predictions were sent to N9831 investigators and accuracy of predictions were tested in pts enrolled into arms A and C (N=892) using Cox models adjusted for age, nodes, ER/PR status, tumor size, and grade. Recurrence-free survival (RFS) and DFS were used as endpoints. RESULTS Tumors from N9831were placed into one of the three trastuzumab benefit groups based on the 8-gene signature. The N9831 pts in the predicted-large benefit group had a hazard ratio (HR) of 0.47, P=0.0006, pts in the predicted-medium benefit group had an HR of 0.6, P=0.02, and the predicted-low benefit group had an HR of 1.54, P=0.375. The interaction P value was significant at 0.019 in adjusted Cox models. The RFS at 10 years for trastuzumab-treated pts was 72%, 83%, and 83% in the low, medium, and large benefit groups, respectively. CONCLUSIONS The 8-gene signature developed in a discovery cohort and validated in an independent cohort of B-31 pts has now been validated in N9831. Many anti-HER2 therapies such as lapatinib, afatinib, neratinib, pertuzumab, and TDM-1 have been approved for treatment in metastatic breast cancer pts and although these agents have shown responses, the actual improvements in outcomes in pts is variable and it is not known which pts actually receive benefit. Thus this signature may be clinically useful in identifying pts who may benefit from additional treatment beyond trastuzumab or for stratification of pts enrolled into clinical trials testing new anti-HER2 therapies. SUPPORT U10CA180868, -180822, UG1CA189867, U24CA196067, the PA DOH, which disclaims certain responsibilities, Genentech, Inc., and the Breast Cancer Research Foundation. Citation Format: Pogue-Geile KL, Song N, Serie DJ, Thompson EA. The NSABP/NRG 8-gene signature accurately predicts degree of benefit from trastuzumab in Alliance/NCCTG N9831: Validation of the 8-gene signature in an independent clinical trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD3-18.